BTIG and H.C. Wainwright & Co. are acting as co-lead managers with D. Boral Capital acting as co-manager for the offering.

D. Boral Capital keeps a Buy rating on Anavex Life Sciences (AVXL) with a $46 price target after Cassava Sciences’ (SAVA) Phase 3 trial for simufilam in mild-to-moderate Alzheimer’s disease ...

D. Boral Capital lowered the firm’s price target on Carisma Therapeutics (CARM) to $12 from $24 and keeps a Buy rating on the shares after the company announced it is discontinuing the ...